{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:47:32Z","timestamp":1790768852864,"version":"4.1.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T00:00:00Z","timestamp":1371686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0066388","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T22:56:50Z","timestamp":1371769010000},"page":"e66388","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Antioxidant N-Acetylcysteine Prevents HIF-1 Stabilization under Hypoxia In Vitro but Does Not Affect Tumorigenesis in Multiple Breast Cancer Models In Vivo"],"prefix":"10.1371","volume":"8","author":[{"given":"Jaclyn","family":"Sceneay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira C. P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S. F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D. L.","family":"Bowtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"GL Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"X Lu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2013a key regulatory factor in tumour growth","volume":"2","author":"AL Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"RK Jain","year":"2005","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e1000394","DOI":"10.1371\/journal.pcbi.1000394","article-title":"Structural adaptation and heterogeneity of normal and tumor microvascular networks","volume":"5","author":"AR Pries","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"WR Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10555-007-9056-0","article-title":"Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment","volume":"26","author":"BJ Moeller","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"N Rohwer","year":"2011","journal-title":"Drug Resist Updat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"GL Semenza","year":"1999","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"GL Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"C1172","DOI":"10.1152\/ajpcell.1996.271.4.C1172","article-title":"Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension","volume":"271","author":"BH Jiang","year":"1996","journal-title":"Am J Physiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","article-title":"Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway","volume":"95","author":"LE Huang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1074\/jbc.274.10.6519","article-title":"Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway","volume":"274","author":"PJ Kallio","year":"1999","journal-title":"J Biol Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"S Salceda","year":"1997","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: role of the HIF system","volume":"9","author":"CW Pugh","year":"2003","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"H Tian","year":"1997","journal-title":"Genes Dev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V92.7.2260","article-title":"Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha","volume":"92","author":"MS Wiesener","year":"1998","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"GL Semenza","year":"2010","journal-title":"Oncogene"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"AJ Majmundar","year":"2010","journal-title":"Mol Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"RK Bruick","year":"2001","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"AC Epstein","year":"2001","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1172\/JCI5912","article-title":"Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha","volume":"103","author":"AY Yu","year":"1999","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"M Ivan","year":"2001","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"P Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"PH Maxwell","year":"1999","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.0812801106","article-title":"Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells","volume":"106","author":"K Lee","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.1158\/0008-5472.CAN-05-4598","article-title":"Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha","volume":"66","author":"DZ Qian","year":"2006","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","article-title":"Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway","volume":"277","author":"JS Isaacs","year":"2002","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"GV Thomas","year":"2006","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/0008-5472.CAN-04-4589","article-title":"Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer","volume":"65","author":"M Liu","year":"2005","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1038\/sj.onc.1208625","article-title":"The antiepidermal growth factor receptor monoclonal antibody cetuximab\/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression","volume":"24","author":"RB Luwor","year":"2005","journal-title":"Oncogene"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-11-0682","article-title":"Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors","volume":"17","author":"S Kummar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ccr.2007.08.004","article-title":"HIF-dependent antitumorigenic effect of antioxidants in vivo","volume":"12","author":"P Gao","year":"2007","journal-title":"Cancer Cell"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Brok J, Buckley N, Gluud C (2006) Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev: CD003328.","DOI":"10.1002\/14651858.CD003328.pub2"},{"key":"ref35","first-page":"265","article-title":"N-acetylcysteine: multiple clinical applications","volume":"80","author":"PJ Millea","year":"2009","journal-title":"Am Fam Physician"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0002-9440(10)63727-3","article-title":"N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer","volume":"164","author":"A Agarwal","year":"2004","journal-title":"Am J Pathol"},{"key":"ref37","first-page":"8171","article-title":"Inhibition of angiogenesis-driven Kaposi\u2019s sarcoma tumor growth in nude mice by oral N-acetylcysteine","volume":"61","author":"A Albini","year":"2001","journal-title":"Cancer Res"},{"key":"ref38","unstructured":"Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, <etal>et al<\/etal>.. (1994) Clinical development plan: N-Acetyl-l-cysteine. J Cell Biochem Suppl 20: 63\u201373."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3","article-title":"Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models","volume":"67","author":"S De Flora","year":"1996","journal-title":"Int J Cancer"},{"key":"ref40","first-page":"217","article-title":"Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice","volume":"13","author":"F D\u2019Agostini","year":"1998","journal-title":"Int J Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2125.2005.02523.x","article-title":"N-acetylcysteine \u2013 passe-partout or much ado about nothing?","volume":"61","author":"ML Aitio","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e38388","DOI":"10.1371\/journal.pone.0038388","article-title":"Time-dependent stabilization of hypoxia inducible factor-1alpha by different intracellular sources of reactive oxygen species","volume":"7","author":"M Calvani","year":"2012","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.2910610121","article-title":"Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine","volume":"61","author":"A Albini","year":"1995","journal-title":"Int J Cancer"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, <etal>et al<\/etal>.. (2012) Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis.","DOI":"10.1007\/s10585-012-9519-8"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1158\/0008-5472.CAN-11-3310","article-title":"Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy","volume":"72","author":"CS Wong","year":"2012","journal-title":"Cancer Res"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, <etal>et al<\/etal>.. (2012) Primary Tumor Hypoxia Recruits CD11b+\/Ly6Cmed\/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche. Cancer Research.","DOI":"10.1158\/0008-5472.CAN-11-3873"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3181\/00379727-77-18779","article-title":"Sustained enhanced growth of carcinoma EO771 in C57 black mice","volume":"77","author":"AE Casey","year":"1951","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006689719505","article-title":"A novel orthotopic model of breast cancer metastasis to bone","volume":"17","author":"M Lelekakis","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/onc.2008.382","article-title":"Inhibition of Siah ubiquitin ligase function","volume":"28","author":"A Moller","year":"2009","journal-title":"Oncogene"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, <etal>et al<\/etal>.. (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med.","DOI":"10.1038\/nm.2830"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-60327-345-9_12","article-title":"Immunohistochemical detection of tumour hypoxia","volume":"611","author":"RJ Young","year":"2010","journal-title":"Methods Mol Biol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/bcr2615","article-title":"ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67","volume":"12","author":"VJ Tuominen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0277-5379(82)90035-9","article-title":"Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity","volume":"18","author":"LR Morgan","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000226912","article-title":"Safety of high-dose vitamin A. Randomized trial on lung cancer chemoprevention","volume":"48","author":"U Pastorino","year":"1991","journal-title":"Oncology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s000180300001","article-title":"Molecular mechanisms of N-acetylcysteine actions","volume":"60","author":"M Zafarullah","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"ref56","first-page":"669","article-title":"Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations","volume":"52","author":"L Allegra","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00003246-200102000-00009","article-title":"N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients","volume":"29","author":"AR Heller","year":"2001","journal-title":"Crit Care Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1073\/pnas.97.16.8841","article-title":"Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens","volume":"97","author":"C Nathan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00024382-199712000-00007","article-title":"N-acetyl cysteine attenuates acute lung injury in the rat","volume":"8","author":"CJ Davreux","year":"1997","journal-title":"Shock"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00109-003-0476-1","article-title":"Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress","volume":"81","author":"G Mantovani","year":"2003","journal-title":"J Mol Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1704143","article-title":"N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation","volume":"32","author":"F Sjoo","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jnci\/92.12.977","article-title":"EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups","volume":"92","author":"N van Zandwijk","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref63","first-page":"919","article-title":"Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial","volume":"70","author":"PJ Loehrer Sr","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0167-8140(92)90267-X","article-title":"N-acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: a feasibility study","volume":"25","author":"P Maasilta","year":"1992","journal-title":"Radiother Oncol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0022-5347(05)65759-X","article-title":"SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial","volume":"166","author":"EA Klein","year":"2001","journal-title":"J Urol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"EA Klein","year":"2011","journal-title":"JAMA"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0066388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:40:24Z","timestamp":1595972424000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0066388"}},"subtitle":[],"editor":[{"given":"Victoria","family":"Lawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,20]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0066388","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,20]]}}}